Study of ALS Reversals 4: LifeTime Exposures
Public ClinicalTrials.gov record NCT03706391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Hypothesis: There exists patients who have met ALS or PMA diagnostic criteria and subsequently experienced robust and sustained improvement, i.e. a "reversal." Thirty-eight of these patients were identified in the prior Duke University study, Documentation of Known ALS Reversals (St.A.R. Protocol 1, Duke IRB Pro00076395). The investigators hypothesize these patients have had different environmental exposures than patients with typically progressive ALS. Identification of specific environmental influences may point to exposures which are protective or exposure that lead to the development of a rare and novel reversible ALS-like disease. Objective: This study seeks to identify environmental exposures associated with ALS reversals.
Study identification
- NCT ID
- NCT03706391
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 25 participants
Conditions and interventions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2018
- Primary completion
- May 31, 2020
- Completion
- May 31, 2020
- Last update posted
- Jan 19, 2023
2018 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Duke ALS Clinic / DUSOM Dept of Neurology / DUHS | Durham | North Carolina | 27705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Amyotrophic Lateral Sclerosis trials
Other public records listing Amyotrophic Lateral Sclerosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06609213: Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS Recruiting
- NCT02327845: Phenotype, Genotype & Biomarkers in ALS and Related Disorders Active, not recruiting
- NCT07287397: Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS Recruiting
- NCT04297683: HEALEY ALS Platform Trial - Master Protocol Recruiting
- NCT06735014: Multicenter ALS Imaging Study Recruiting
- NCT03362658: Novel MRI Biomarkers for Monitoring Disease Progression in ALS Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03706391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03706391 live on ClinicalTrials.gov.